Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

The Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI)

Logo

The ODDI was founded in 2015

We have a team of 40 staff and students, comprising biologists, screening scientists and medicinal chemists.

We have partnered three drug discovery projects to date.

The Alzheimer's Research UK Oxford Drug Discovery Institute couples the deep disease knowledge and biology expertise of the academic community with high quality, innovative drug discovery technologies.

The Oxford Drug Discovery Institute seeks to translate academic research into drug discovery projects. We perform in vitro target validation, develop screening assays, and screen our compound libraries to develop small molecule modulators of targets that may hold therapeutic potential for the treatment of neurodegenerative diseases. © Alzheimer's Research UK
The Oxford Drug Discovery Institute

Overview

Housed within the Centre for Medicines Discovery, Nuffield Department of Medicine at the University of Oxford Old Road Campus, the Oxford Drug Discovery Institute is uniting collaborative efforts for target identification with sophisticated target development capabilities. We are looking for academic researchers who have targets and ideas with translational potential, keen to partner with us to fast-track these ideas towards new medicines.

We focus on validating targets that influence neuroinflammatory processes and organelle dysfunction in Alzheimer's and Parkinson's disease, as well as other neurodegenerative conditions. We have a core biology team with expertise in validating targets using iPSC technologies, and a dedicated assay development and screening team, who support our portfolio of projects and develop bespoke screening assays to identify compounds that can be developed by our medicinal chemists. 

 

For further information, please contact our Chief Scientific Officer, Dr Emma Mead (emma.mead@cmd.ox.ac.uk), or our Assistant Project Manager, Kate Humphrey (kate.humphrey@cmd.ox.ac.uk)

Our team

Selected publications